8-K: Disc Medicine Holds 2024 Annual Meeting, Elects Directors and Ratifies Auditor
Annual Meeting Results
Disc Medicine's 2024 Annual Meeting saw the election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
Summary
- Disc Medicine held its 2024 Annual Meeting of Stockholders on June 12, 2024.
- Stockholders voted on two proposals: the election of Class I directors and the ratification of the company's independent auditor.
- Mona Ashiya, Ph.D. and Kevin Bitterman, Ph.D. were elected as Class I directors for a three-year term ending in 2027.
- The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
- No other matters were submitted to a vote at the meeting.
Sentiment
Score: 7
Explanation: The document reflects standard corporate governance procedures, indicating a stable and routine operation. There are no indications of any issues or concerns.
Positives
- The election of directors and ratification of the auditor were successfully completed.
- The high number of votes in favor of the proposals indicates strong shareholder support.
Management Comments
- John Quisel, J.D., Ph.D., Chief Executive Officer, signed the report on behalf of Disc Medicine, Inc.
Industry Context
This is a standard corporate governance procedure for a publicly traded company, ensuring accountability and oversight.
Comparison to Industry Standards
- The election of directors and ratification of auditors are standard practices for publicly traded companies like Disc Medicine.
- The voting results are typical for such meetings, with a majority of votes cast in favor of the proposals.
- Companies such as Alnylam Pharmaceuticals and BioMarin Pharmaceutical also hold annual meetings with similar voting procedures.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class I Director | N/A | Mona Ashiya, Ph.D. | 2024-06-12 | Election at Annual Meeting |
| Class I Director | N/A | Kevin Bitterman, Ph.D. | 2024-06-12 | Election at Annual Meeting |
Stakeholder Impact
- Shareholders have exercised their voting rights to elect directors and ratify the auditor.
- The successful completion of the annual meeting provides transparency and accountability to stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2024-05-01 | The Company's Definitive Proxy Statement on Schedule 14A was filed with the Securities and Exchange Commission. |
| 2024-06-12 | Disc Medicine held its 2024 Annual Meeting of Stockholders. |
| 2024-06-14 | Date of the 8-K report filing. |
| 2027 | The term for the newly elected directors will end at the annual meeting of stockholders to be held in 2027. |
| 2024-12-31 | The fiscal year end for which Ernst & Young LLP was ratified as the independent auditor. |
Keywords
Annual Meeting, Director Election, Auditor Ratification, Corporate Governance, Shareholder Vote, Disc Medicine, Ernst & Young
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.